Recent Updates
Recently added Catalysts
SMMT Positive Sentiment

Summit Therapeutics and Lunit Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development

Friday, October 23, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Summit Therapeutics and Lunit announced a research agreement to apply Lunit's AI-powered SCOPE IO platform for tumor microenvironment analysis. This collaboration supports Summit's immuno-oncology development programs with ivonescimab. The initiative will analyze hematoxylin and eosin-stained whole-slide images to characterize tumor features.

Market Sentiment Analysis

POSITIVE FACTORS

  • Summit Therapeutics partners with Lunit for AI analysis.
  • Agreement supports immuno-oncology development programs.
  • Focus on tumor microenvironment characterization.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+48%
120-day peak, hindsight
Typical move
39.8%
average across 4 past catalysts
Cash runway
~12 mo
Low dilution risk
Lead asset
Ivonescimab
NDA/BLA · Non-Squamous Non-small Cell Lung Cancer

Full Press Release Details

MIAMI & SEOUL, South Korea--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) and Lunit Inc. (KRX: 328130) today announced a research agreement to evaluate the use of Lunit SCOPE IO, Lunit’s AI-powered pathology platform, for tumor microenvironment analysis in support of Summit’s immuno-oncology development programs with ivonescimab. The effort will focus on applying Lunit SCOPE IO to hematoxylin and eosin-stained (H&E) whole-slide images to characterize tumor microenvironment featur

Frequently Asked Questions

What is the goal of the Summit-Lunit deal?

The partnership aims to evaluate Lunit's AI platform for tumor microenvironment analysis in immuno-oncology.

Which AI platform is Lunit providing?

Lunit will provide its SCOPE IO platform, an AI-powered pathology tool for analyzing tumor features.

What type of images will be analyzed?

The analysis focuses on hematoxylin and eosin-stained whole-slide images to characterize the tumor microenvironment.

Which drug is linked to this research?

The research supports Summit's immuno-oncology development programs specifically involving the drug ivonescimab.

ShareAdd on Google
Tags: SMMT Summit Therapeutics Lunit immuno-oncology ivonescimab SCOPE IO
Last updated: Oct 23, 2026

Biotech snapshot

Cash runway
$691M liquidity · $47M/mo burn
~12 mo
Low dilution risk
Lead asset
IvonescimabNDA/BLA
Non-Squamous Non-small Cell Lung Cancer →

Catalyst track record

+48%
best trade around SMMT's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for SMMT.

See every catalyst's timing & PoA →